Table 5. Median (95% CI) lifetime cost, ESA dosage, life years, QALYs, and ICERs from probabilistic sensitivity analysis of incremental cost-effectiveness for different anemia treatment targets.
| Target Hb (g/dl) | Lifetime Costs ($) | ESA Dosage (units/week) | Life Years | QALYs | ICER ($/QALY) |
|---|---|---|---|---|---|
| No treatment | 92,219 (88,264–97,651) | NA | 6.46 (6.20–6.72) | 4.47 (4.31–4.64) | NA |
| 10.0 | 98,616 (94,121–103,424) | 447 (421–472) | 6.75 (6.50–7.02) | 4.64 (4.48–4.81) | 30,480 (-54,890–106,346) |
| 10.5 | 102,750 (98,028–107,875) | 1,232 (1,201–1,265) | 6.92 (6.63–7.20) | 4.76 (4.58–4.94) | 30,059 (119,348–221,861) |
| 11.0 | 108,540 (103,633–15,459) | 3,873 (3,785–3,965) | 6.88 (6.61–7.14) | 4.76 (4.60–4.94) | - |
| 11.5 | 115,255 (110,213–20,290) | 7,476 (7,324–7,642) | 6.75 (6.49–7.01) | 4.71 (4.53–4.87) | Dominated |
| 12.0 | 123,360 (117,728–28,864) | 11,907 (11,683–12,134) | 6.57 (6.29–6.83) | 4.61 (4.43–4.77) | Dominated |
| 12.5 | 132,372 (126,408–38,023) | 17,221 (16,940–17,513) | 6.33 (6.09–6.58) | 4.46 (4.30–4.63) | Dominated |
| 13.0 | 141,300 (135,035–47,232) | 23,492 (23,163–23,839) | 6.01 (5.77–6.24) | 4.24 (4.08–4.40) | Dominated |
CI, confidence interval; ESA, erythropoietin stimulating agents; Hb, hemoglobin; ICER, incremental cost-effectiveness ratio; QALY, quality adjusted years of life; NA, not applicable.